Lycia Therapeutics, Inc. (LYCA)

Data as of Oct 30, 2026, from SEC Form 4 filings.

NasdaqNet insider buying (90d)Watch LYCA

See up to 3 months of LYCA. The 7-day demo opens the 1M and 3M ranges and puts LYCA on your watchlist.

Latest LYCA insider trades

Venrock Healthcare Capital Partners III, L.P. - 10% Owner
Open-market purchase$267K
Oct 28, 2026
Venrock Healthcare Capital Partners III, L.P. - 10% Owner

About Lycia Therapeutics, Inc. (LYCA)

Lycia Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapeutics designed to degrade disease-causing extracellular proteins, with an initial focus on addressing autoimmune, inflammatory and allergic diseases.

Listed: 2026
Exchange: Nasdaq
Sector: Health Care

https://www.lyciatx.com SEC filings for LYCA on EDGAR

LYCA Form 4 activity by transaction type, last 90 days

Form 4 transaction type	Transactions	Shares	Total value
Open-market purchase	11	2,070,444	$38.30M
Grant or award	11	1,251,987
Other acquisition / disposition	7	65,030,776

LYCA insider transactions (Form 4)

11 Form 4 filings on record, the earliest from Oct 26, 2026, newest first.

Traded	Insider	Transaction	Security	Shares	Price	Value
Oct 28, 2026	Venrock Healthcare Capital Partners III, L.P. - 10% Owner	Open-market purchase	Common Stock	10,570^{footnote F1}	$25.23^{footnote F2}	$267K
Oct 28, 2026	Venrock Healthcare Capital Partners III, L.P. - 10% Owner	Open-market purchase	Common Stock	4,430^{footnote F7}	$25.97^{footnote F8}	$115K
Oct 29, 2026	Venrock Healthcare Capital Partners III, L.P. - 10% Owner	Open-market purchase	Common Stock	1,000^{footnote F10}	$26.33^{footnote F11}	$26K
Oct 30, 2026	Venrock Healthcare Capital Partners III, L.P. - 10% Owner	Open-market purchase	Common Stock	8,804^{footnote F13}	$26.27^{footnote F14}	$231K
Oct 30, 2026	Venrock Healthcare Capital Partners III, L.P. - 10% Owner	Open-market purchase	Common Stock	200^{footnote F16}	$26.86^{footnote F17}	$5K
Footnote F1 (shares): Consists of (i) 4,804 shares held by Venrock Healthcare Capital Partners III, L.P. ("VHCP3"); (ii) 481 shares held by VHCP Co-Investment Holdings III,LLC ("VHCP Co-3"); and (iii) 5,285 shares held by Venrock Healthcare Capital Partners EG, L.P. ("VHCP EG"). Footnote F2 (price): The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $24.77 to $25.50 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of… Full note on SEC EDGAR Footnote F7 (shares): Consists of (i) 2,013 shares held by VHCP3; (ii) 202 shares held by VHCP Co-3; and (iii) 2,215 shares held by VHCP EG. Footnote F8 (price): The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $25.88 to $26.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of… Full note on SEC EDGAR Footnote F10 (shares): Consists of (i) 455 shares held by VHCP3; (ii) 45 shares held by VHCP Co-3; and (iii) 500 shares held by VHCP EG. Footnote F11 (price): The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $26.26 to $26.40 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of… Full note on SEC EDGAR Footnote F13 (shares): Consists of (i) 4,001 shares held by VHCP3; (ii) 401 shares held by VHCP Co-3; and (iii) 4,402 shares held by VHCP EG. Footnote F14 (price): The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $25.70 to $26.64 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of… Full note on SEC EDGAR Footnote F16 (shares): Consists of (i) 91 shares held by VHCP3; (ii) 9 shares held by VHCP Co-3; and (iii) 100 shares held by VHCP EG. Footnote F17 (price): The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $26.84 to $26.87 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of… Full note on SEC EDGAR
Oct 26, 2026	Versant Ventures VII GP, L.P. - 10% Owner	Other	Common Stock	5,631,425	-^{footnote F1}	-
Oct 26, 2026	Versant Ventures VII GP, L.P. - 10% Owner	Other	Common Stock	1,393,882	-^{footnote F1}	-
Oct 26, 2026	Versant Ventures VII GP, L.P. - 10% Owner	Other	Series A Preferred Stock	25,390,410	-^{footnote F1}	-
Oct 26, 2026	Versant Ventures VII GP, L.P. - 10% Owner	Other	Series B Preferred Stock	6,284,597	-^{footnote F1}	-
Footnote F1 (price): Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-0.221793422 basis upon the closing of the Issuer's initial public offering on October 26, 2026, without payment of consideration. The… Full note on SEC EDGAR
Oct 23, 2026	Venrock Healthcare Capital Partners III, L.P. - 10% Owner	Open-market purchase	Common Stock	24,560^{footnote F1}	$25.68^{footnote F2}	$631K
Oct 23, 2026	Venrock Healthcare Capital Partners III, L.P. - 10% Owner	Open-market purchase	Common Stock	28,379^{footnote F5}	$26.11^{footnote F6}	$741K
Oct 26, 2026	Venrock Healthcare Capital Partners III, L.P. - 10% Owner	Other	Common Stock	4,779,793^{footnote F8}	-^{footnote F9}	-
Oct 26, 2026	Venrock Healthcare Capital Partners III, L.P. - 10% Owner	Open-market purchase	Common Stock	1,944,444^{footnote F12}	$18.00	$35.00M
Oct 26, 2026	Venrock Healthcare Capital Partners III, L.P. - 10% Owner	Open-market purchase	Common Stock	8,261^{footnote F14}	$26.97^{footnote F15}	$223K
Oct 27, 2026	Venrock Healthcare Capital Partners III, L.P. - 10% Owner	Open-market purchase	Common Stock	8,729^{footnote F17}	$25.84^{footnote F18}	$226K
Oct 27, 2026	Venrock Healthcare Capital Partners III, L.P. - 10% Owner	Open-market purchase	Common Stock	31,067^{footnote F20}	$26.84^{footnote F21}	$834K
Oct 26, 2026	Venrock Healthcare Capital Partners III, L.P. - 10% Owner	Other	Series C Preferred Stock	17,142,578^{footnote F23}	$0.00	-
Oct 26, 2026	Venrock Healthcare Capital Partners III, L.P. - 10% Owner	Other	Series D Preferred Stock	4,408,091^{footnote F25}	$0.00	-
Footnote F1 (shares): Consists of (i) 11,163 shares held by Venrock Healthcare Capital Partners III, L.P. ("VHCP3"); (ii) 1,118 shares held by VHCP Co-Investment Holdings III,LLC ("VHCP Co-3"); and (iii) 12,279 shares held by Venrock Healthcare Capital Partners EG, L.P. ("VHCP EG"). Footnote F2 (price): The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $25.00 to $25.99 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of… Full note on SEC EDGAR Footnote F5 (shares): Consists of (i) 12,898 shares held by VHCP3; (ii) 1,292 shares held by VHCP Co-3; and (iii) 14,189 shares held by VHCP EG. Footnote F6 (price): The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $26.00 to $26.25 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of… Full note on SEC EDGAR Footnote F8 (shares): Consists of (i) 828,479 shares held by VHCP3; (ii) 82,885 shares held by VHCP Co-3; (iii) 3,216,639 shares held by VHCP EG; and (iv) 651,790 shares held by Venrock Healthcare Capital Partners XP, L.P. ("VHCP XP"). Footnote F9 (price): Each share of Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-0.221793422 basis upon the closing of the Issuer's initial public offering on October 26, 2026 without payment of consideration. The… Full note on SEC EDGAR Footnote F12 (shares): Consists of (i) 883,750 shares held by VHCP3; (ii) 88,472 shares held by VHCP Co-3; and (iii) 972,222 shares held by VHCP EG. Footnote F14 (shares): Consists of (i) 3,755 shares held by VHCP3; (ii) 376 shares held by VHCP Co-3; and (iii) 4,130 shares held by VHCP EG. Footnote F15 (price): The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $26.82 to $27.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of… Full note on SEC EDGAR Footnote F17 (shares): Consists of (i) 3,967 shares held by VHCP3; (ii) 397 shares held by VHCP Co-3; and (iii) 4,365 shares held by VHCP EG. Footnote F18 (price): The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $25.28 to $26.27 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of… Full note on SEC EDGAR Footnote F20 (shares): Consists of (i) 14,120 shares held by VHCP3; (ii) 1,414 shares held by VHCP Co-3; and (iii) 15,533 shares held by VHCP EG. Footnote F21 (price): The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $26.28 to $27.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of… Full note on SEC EDGAR Footnote F23 (shares): Consists of (i) 3,735,368 shares held by VHCP3; (ii) 373,708 shares held by VHCP Co-3; and (iii) 13,033,502 shares held by VHCP EG. Footnote F25 (shares): Consists of (i) 1,469,363 shares held by VHCP EG and (ii) 2,938,728 shares held by VHCP XP.
Aug 11, 2026	Laurent Fischer - Director	Grant or award	Stock Option (Right to Buy)	13,307	$0.00	-
Oct 22, 2026	Laurent Fischer - Director	Grant or award	Stock Option (Right to Buy)	20,000	$0.00	-
Aug 11, 2026	Jane Henderson - Director	Grant or award	Stock Option (Right to Buy)	57,666	$0.00	-
Oct 22, 2026	Jane Henderson - Director	Grant or award	Stock Option (Right to Buy)	20,000	$0.00	-
Aug 11, 2026	William Jl Rieflin - Director	Grant or award	Stock Option (Right to Buy)	24,840	$0.00	-
Oct 22, 2026	William Jl Rieflin - Director	Grant or award	Stock Option (Right to Buy)	20,000	$0.00	-
Aug 11, 2026	Sofia Touami - Officer	Grant or award	Stock Option (Right to Buy)	68,755	$0.00	-
Aug 11, 2026	Steven Staben - Officer	Grant or award	Stock Option (Right to Buy)	110,896	$0.00	-
Aug 11, 2026	Chin Hyok Lee - Officer	Grant or award	Stock Option (Right to Buy)	73,191	$0.00	-
Aug 11, 2026	Amy Bachrodt - Officer	Grant or award	Stock Option (Right to Buy)	399,746	$0.00	-
Aug 11, 2026	Aetna Wun Trombley - Officer	Grant or award	Stock Option (Right to Buy)	443,586	$0.00	-

Recent LYCA Form 8-K filings

Read LYCA company news

Oct 26, 2026Item 5.03, 9.01

Read the filing on SEC EDGAR

LYCA insider trading FAQ

What is the latest insider trade for LYCA?

Lycia Therapeutics, Inc. (LYCA) had 11 insider filings in the last 90 days, with the most recent on 30 October 2026. The full record for LYCA runs to 11 Form 4 filings, the earliest from 26 October 2026. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.

How many insiders are buying LYCA stock?

11 insider purchases of LYCA were filed in the last 90 days, totaling $38.30M.

How many insiders are selling LYCA stock?

No insider sales of LYCA were filed in the last 90 days.

Where can I see LYCA SEC filings (Form 4, 10-K, 10-Q, 8-K)?

This page collects LYCA Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.

More Health Care companies with insider activity

Recent insider filings

The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.

Oct 30, 2026 - Venrock Healthcare Capital Partners III, L.P. view on EDGAR
Oct 28, 2026 - Versant Ventures VII GP, L.P. view on EDGAR
Oct 27, 2026 - Venrock Healthcare Capital Partners III, L.P. view on EDGAR
Oct 26, 2026 - Laurent Fischer view on EDGAR
Oct 26, 2026 - Jane Henderson view on EDGAR
Oct 26, 2026 - William Jl Rieflin view on EDGAR
Oct 26, 2026 - Sofia Touami view on EDGAR
Oct 26, 2026 - Steven Staben view on EDGAR
Oct 26, 2026 - Chin Hyok Lee view on EDGAR

Related companies with recent insider activity

Learn more

How to read insider buying signals: What an open-market purchase by an insider can and cannot tell you.
Insider activity in Health Care: Where LYCA's peers are being bought and sold.
Every recent Form 4: The market-wide feed, updated as filings arrive from SEC EDGAR.

Follow LYCA with a 7-day demo

LYCA on your watchlist
Every LYCA Form 4 filing on record
Up to 3 months of LYCA price history
The daily trading plan of ranked insider buys, on a delay, with the plan archive

Start 7-day demoCard required. Your card is never charged for the demo.

Form 4 transaction type

Transactions

Total value

Open-market purchase

2,070,444

$38.30M

Grant or award

1,251,987

Other acquisition / disposition

65,030,776

Traded

Insider

Transaction

Security

Price

Value

Oct 28, 2026

Venrock Healthcare Capital Partners III, L.P. - 10% Owner

Open-market purchase

Common Stock

10,570^{footnote F1}

$25.23^{footnote F2}

$267K

Oct 28, 2026

Venrock Healthcare Capital Partners III, L.P. - 10% Owner

Open-market purchase

Common Stock

4,430^{footnote F7}

$25.97^{footnote F8}

$115K

Oct 29, 2026

Venrock Healthcare Capital Partners III, L.P. - 10% Owner

Open-market purchase

Common Stock

1,000^{footnote F10}

$26.33^{footnote F11}

$26K

Oct 30, 2026

Venrock Healthcare Capital Partners III, L.P. - 10% Owner

Open-market purchase

Common Stock

8,804^{footnote F13}

$26.27^{footnote F14}

$231K

Oct 30, 2026

Venrock Healthcare Capital Partners III, L.P. - 10% Owner

Open-market purchase

Common Stock

200^{footnote F16}

$26.86^{footnote F17}

$5K

Footnote F1 (shares): Consists of (i) 4,804 shares held by Venrock Healthcare Capital Partners III, L.P. ("VHCP3"); (ii) 481 shares held by VHCP Co-Investment Holdings III,LLC ("VHCP Co-3"); and (iii) 5,285 shares held by Venrock Healthcare Capital Partners EG, L.P. ("VHCP EG").
Footnote F2 (price): The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $24.77 to $25.50 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of… Full note on SEC EDGAR
Footnote F7 (shares): Consists of (i) 2,013 shares held by VHCP3; (ii) 202 shares held by VHCP Co-3; and (iii) 2,215 shares held by VHCP EG.
Footnote F8 (price): The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $25.88 to $26.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of… Full note on SEC EDGAR
Footnote F10 (shares): Consists of (i) 455 shares held by VHCP3; (ii) 45 shares held by VHCP Co-3; and (iii) 500 shares held by VHCP EG.
Footnote F11 (price): The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $26.26 to $26.40 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of… Full note on SEC EDGAR
Footnote F13 (shares): Consists of (i) 4,001 shares held by VHCP3; (ii) 401 shares held by VHCP Co-3; and (iii) 4,402 shares held by VHCP EG.
Footnote F14 (price): The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $25.70 to $26.64 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of… Full note on SEC EDGAR
Footnote F16 (shares): Consists of (i) 91 shares held by VHCP3; (ii) 9 shares held by VHCP Co-3; and (iii) 100 shares held by VHCP EG.
Footnote F17 (price): The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $26.84 to $26.87 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of… Full note on SEC EDGAR

Oct 26, 2026

Versant Ventures VII GP, L.P. - 10% Owner

Other

Common Stock

5,631,425

-^{footnote F1}

Oct 26, 2026

Versant Ventures VII GP, L.P. - 10% Owner

Other

Common Stock

1,393,882

-^{footnote F1}

Oct 26, 2026

Versant Ventures VII GP, L.P. - 10% Owner

Other

Series A Preferred Stock

25,390,410

-^{footnote F1}

Oct 26, 2026

Versant Ventures VII GP, L.P. - 10% Owner

Other

Series B Preferred Stock

6,284,597

-^{footnote F1}

Footnote F1 (price): Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-0.221793422 basis upon the closing of the Issuer's initial public offering on October 26, 2026, without payment of consideration. The… Full note on SEC EDGAR

Oct 23, 2026

Venrock Healthcare Capital Partners III, L.P. - 10% Owner

Open-market purchase

Common Stock

24,560^{footnote F1}

$25.68^{footnote F2}

$631K

Oct 23, 2026

Venrock Healthcare Capital Partners III, L.P. - 10% Owner

Open-market purchase

Common Stock

28,379^{footnote F5}

$26.11^{footnote F6}

$741K

Oct 26, 2026

Venrock Healthcare Capital Partners III, L.P. - 10% Owner

Other

Common Stock

4,779,793^{footnote F8}

-^{footnote F9}

Oct 26, 2026

Venrock Healthcare Capital Partners III, L.P. - 10% Owner

Open-market purchase

Common Stock

1,944,444^{footnote F12}

$18.00

$35.00M

Oct 26, 2026

Venrock Healthcare Capital Partners III, L.P. - 10% Owner

Open-market purchase

Common Stock

8,261^{footnote F14}

$26.97^{footnote F15}

$223K

Oct 27, 2026

Venrock Healthcare Capital Partners III, L.P. - 10% Owner

Open-market purchase

Common Stock

8,729^{footnote F17}

$25.84^{footnote F18}

$226K

Oct 27, 2026

Venrock Healthcare Capital Partners III, L.P. - 10% Owner

Open-market purchase

Common Stock

31,067^{footnote F20}

$26.84^{footnote F21}

$834K

Oct 26, 2026

Venrock Healthcare Capital Partners III, L.P. - 10% Owner

Other

Series C Preferred Stock

17,142,578^{footnote F23}

$0.00

Oct 26, 2026

Venrock Healthcare Capital Partners III, L.P. - 10% Owner

Other

Series D Preferred Stock

4,408,091^{footnote F25}

$0.00

Footnote F1 (shares): Consists of (i) 11,163 shares held by Venrock Healthcare Capital Partners III, L.P. ("VHCP3"); (ii) 1,118 shares held by VHCP Co-Investment Holdings III,LLC ("VHCP Co-3"); and (iii) 12,279 shares held by Venrock Healthcare Capital Partners EG, L.P. ("VHCP EG").
Footnote F2 (price): The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $25.00 to $25.99 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of… Full note on SEC EDGAR
Footnote F5 (shares): Consists of (i) 12,898 shares held by VHCP3; (ii) 1,292 shares held by VHCP Co-3; and (iii) 14,189 shares held by VHCP EG.
Footnote F6 (price): The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $26.00 to $26.25 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of… Full note on SEC EDGAR
Footnote F8 (shares): Consists of (i) 828,479 shares held by VHCP3; (ii) 82,885 shares held by VHCP Co-3; (iii) 3,216,639 shares held by VHCP EG; and (iv) 651,790 shares held by Venrock Healthcare Capital Partners XP, L.P. ("VHCP XP").
Footnote F9 (price): Each share of Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-0.221793422 basis upon the closing of the Issuer's initial public offering on October 26, 2026 without payment of consideration. The… Full note on SEC EDGAR
Footnote F12 (shares): Consists of (i) 883,750 shares held by VHCP3; (ii) 88,472 shares held by VHCP Co-3; and (iii) 972,222 shares held by VHCP EG.
Footnote F14 (shares): Consists of (i) 3,755 shares held by VHCP3; (ii) 376 shares held by VHCP Co-3; and (iii) 4,130 shares held by VHCP EG.
Footnote F15 (price): The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $26.82 to $27.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of… Full note on SEC EDGAR
Footnote F17 (shares): Consists of (i) 3,967 shares held by VHCP3; (ii) 397 shares held by VHCP Co-3; and (iii) 4,365 shares held by VHCP EG.
Footnote F18 (price): The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $25.28 to $26.27 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of… Full note on SEC EDGAR
Footnote F20 (shares): Consists of (i) 14,120 shares held by VHCP3; (ii) 1,414 shares held by VHCP Co-3; and (iii) 15,533 shares held by VHCP EG.
Footnote F21 (price): The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $26.28 to $27.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of… Full note on SEC EDGAR
Footnote F23 (shares): Consists of (i) 3,735,368 shares held by VHCP3; (ii) 373,708 shares held by VHCP Co-3; and (iii) 13,033,502 shares held by VHCP EG.
Footnote F25 (shares): Consists of (i) 1,469,363 shares held by VHCP EG and (ii) 2,938,728 shares held by VHCP XP.